RLX Technology Inc. (NYSE: RLX) Q3 2025 Financial Results: Net Revenue US$158.6 Million; International Business Accounts for 72%

Nov.14.2025
RLX Technology Inc. (NYSE: RLX) announced its unaudited financial results for the third quarter of 2025. The company reported net revenue of RMB 1.13 billion, up 49.3% year-on-year, and adjusted net profit of RMB 295.4 million, up 1.4% quarter-on-quarter. International business contributed 72% of total revenue, reflecting robust financial performance and continued shareholder returns.

Key Points:

  • Q3 net revenue reached RMB 1.129 billion (US$158.6 million), up 49.3% year-on-year and 28.3% quarter-on-quarter.
  • Adjusted net profit was RMB 295.4 million (US$41.5 million), up 1.4% quarter-on-quarter and 12.1% year-on-year.
  • International operations accounted for 72% of total revenue, serving as the main growth driver.
  • Over US$500 million returned to shareholders through buybacks and dividends; financial position remains strong.

 


 

2Firsts, November 14, 2025 — RLX Technology Inc. (NYSE: RLX) today announced its unaudited financial results for the third quarter of 2025. The company achieved strong revenue and profit growth this quarter, with international markets continuing to serve as the primary growth engine.

 

Revenue and Profit Growth

 

In Q3 2025, RLX reported net revenue of RMB 1.129 billion (US$158.6 million), representing a 28.3% quarter-on-quarter and 49.3% year-on-year increase.


On a non-GAAP basis, adjusted net profit was RMB 295.4 million (US$41.5 million), up 1.4% quarter-on-quarter and 12.1% year-on-year.

 

The company attributed its growth to three key factors:

 

  • Continued investment and channel expansion in European markets;
  • Further increase in market share across existing international markets;
  • Accelerated recovery of its China domestic business amid a more orderly and compliant regulatory environment.

 

Management Commentary

 

RLX Founder, Chairperson, and CEO Wang Ying stated that despite ongoing macroeconomic challenges, the company delivered strong and broad-based results this quarter, driven by disciplined execution in international expansion and R&D.


She highlighted that RLX has continued to strengthen its leading position in key Asia-Pacific and European markets through refined retail network investment and localized product strategies. She also noted that improving regulatory clarity in China has fostered a healthier competitive landscape and supported business recovery.

 

Notably, the company’s self-developed oral dissolvable film product was launched in the UK, representing a milestone in RLX’s product diversification and user experience innovation. Wang said the new product embodies years of R&D efforts and underscores the company’s long-term vision to lead next-generation adult consumer experiences.

 

Chief Financial Officer Lu Chao added that international operations accounted for 72% of total revenue in Q3, while adjusted operating profit surged 123.6% year-on-year to RMB 187.8 million (US$26.4 million), reflecting the synergies between international expansion, capital investments in Europe, and domestic business recovery.

 

Lu also noted that as of the end of Q3 2025 (including the cash dividend announced this quarter), RLX has returned over US$500 million to shareholders through share repurchases and dividends, demonstrating its firm commitment to long-term value creation and sustainable profitability.

U.S. Senator Durbin Criticizes FDA’s First Flavored Vape Authorization, Says Trump Administration Conceded to Big Tobacco
U.S. Senator Durbin Criticizes FDA’s First Flavored Vape Authorization, Says Trump Administration Conceded to Big Tobacco
U.S. Senator Dick Durbin on May 13 criticized the Trump Administration’s Food and Drug Administration for approving the sale and marketing of fruit-flavored e-cigarettes for the first time, while also allowing some illegal vaping products to remain on the market. He also linked the regulatory shift to the departure of FDA Commissioner Marty Makary, saying White House pressure on regulators to approve tobacco product applications could create serious public-health consequences.
Regulations
May.15
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA CTP issued a May 7 statement on accelerating product review and improving PMTA efficiency, but did not push it via official X and newsletter until May 13, one day after FDA Commissioner Marty Makary’s resignation was confirmed. FDA has not explained the delay, and no public evidence links it directly to the leadership change. The timing is notable given CTP’s usual 24-hour distribution practice.
Special Report
May.14
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
FDA Center for Tobacco Products Acting Director Bret Koplow said at the American Tobacco and Nicotine Forum that the agency has reduced its premarket tobacco application backlog by about 70% over the past year and eliminated the acceptance queue. He said FDA has reviewed about 27 million applications, but only a small number have been authorized, mainly because most submissions lacked the scientific data needed to demonstrate public health benefits.
Apr.23 by 2FIRSTS.ai
U.S. Company Seeks Cancellation of “Lost Mary” Vape Trademark
U.S. Company Seeks Cancellation of “Lost Mary” Vape Trademark
North Carolina hemp provider JLT Imports Inc. has filed suit in California federal court seeking cancellation of the “Lost Mary” vape trademark held by Chinese company Imiracle (HK) Ltd.
Mar.30 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
    Shenzhen Tobacco Monopoly Bureau Moves to Advance E-Cigarette Regulatory System 2.0
Shenzhen Tobacco Monopoly Bureau Moves to Advance E-Cigarette Regulatory System 2.0
The Shenzhen Tobacco Monopoly Bureau recently held the city’s 2026 e-cigarette regulation work conference to implement higher-level meeting requirements, review the city’s e-cigarette regulatory work in 2025 and during the 14th Five-Year Plan period, assess the current situation, and deploy the rollout of E-cigarette Regulatory System 2.0 across Shenzhen’s tobacco commercial system.
Apr.28 by 2FIRSTS.ai